Krystal Biotech, Inc. KRYS Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s total liabilities?
- Krystal Biotech, Inc. (KRYS) reported total liabilities of $120.24M in Q1 2026.
- How has Krystal Biotech, Inc.'s total liabilities changed year-over-year?
- Krystal Biotech, Inc.'s total liabilities increased by 34.0% year-over-year, from $89.74M to $120.24M.
- What is the long-term trend for Krystal Biotech, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s total liabilities has grown at a 43.5% compound annual growth rate (CAGR), from $18.76M to $114.23M.
- What does total liabilities mean?
- The total amount of money the company owes to all creditors and suppliers.
- How do you interpret total liabilities?
- An increase suggests higher debt financing or operational obligations, while a decrease indicates debt repayment or reduced liabilities.
- How does total liabilities compare across companies?
- Varies significantly based on capital structure and industry; biotech firms often have lower debt levels compared to capital-intensive manufacturing peers.